newsfilter
← Latest News
GlobeNewswire·

Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update

Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conference SUL-DUR NDA submission on track for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 20